Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tividenofusp alfa in Pediatric Hunter Syndrome
NCT04251026Phase 2Active, not recruiting
- Sponsor
- Denali Therapeutics Inc.
- Start
- Jul 2020
- Primary completion
- Feb 2031
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 4
01
Overview
Phase 2, open-label trial of tividenofusp alfa in mucopolysaccharidosis type II (5 cohorts), sponsored by Denali Therapeutics Inc. Primary endpoints: Incidence and severity of treatment-emergent adverse events at 357 weeks, Change from baseline in urine total glycosaminoglycan concentrations at 357 weeks and 2 more. Started Jul 2020; status: active, not recruiting.
02
Drugs
tividenofusp alfa
03
Conditions
mucopolysaccharidosis type II
Beyond the preview
Go deeper on NCT04251026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04251026.